Recommended 2023 Adult Immunization Schedule Published

Changes include new section relating to COVID-19 vaccines, addition of newly licensed vaccine for hepatitis B

THURSDAY, Feb. 9, 2023 (HealthDay News) — The 2023 Adult Immunization Schedule, which includes the COVID-19 vaccine for the first time, was published as a clinical guideline on Feb. 9 in the Annals of Internal Medicine.

Neil Murthy, M.D., M.P.H., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues present the 2023 Advisory Committee on Immunization Practices (ACIP) Recommended Adult Immunization Schedule for Ages 19 Years or Older for the United States.

The authors note that changes to the 2023 adult immunization schedule include a new section relating to the COVID-19 vaccine, which describes primary series recommendations for the general population followed by descriptions for moderately or severely immunocompromised individuals. Vaccine recommendations for Haemophilus influenzae type b, hepatitis A, and human papillomavirus remain unchanged. A newly licensed vaccine for hepatitis B, PreHevbrio was added to the description of the three-dose series. Hepatitis B vaccination is still recommended for all adults aged 19 through 59 years. For the 2022 to 2023 influenza season, routine annual vaccination is recommended for all aged 6 months and older without contraindications. Any one of the quadrivalent high-dose inactivated influenza vaccine, quadrivalent recombinant influenza vaccine, or quadrivalent adjuvanted inactivated influenza vaccine is preferred for adults aged 65 years or older; if none of these three are available, any age-appropriate vaccine should be used. A new polio vaccination section was added to address recommendations for adults at increased risk for poliovirus exposure.

“The purpose of the immunization schedule, published annually, is to consolidate and summarize updates to ACIP recommendations on vaccination of adults and to assist providers in implementing current ACIP recommendations,” the authors write.

One author disclosed financial ties to PathoVax.

Abstract/Full Text

Page 1 of 1